AXSM

Axsome Therapeutics, Inc.

76.47 USD
-0.07 (-0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Axsome Therapeutics, Inc. stock is up 16.36% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
25 Apr 15:25 17 May, 2024 95.00 PUT 15 0
26 Apr 19:34 17 Jan, 2025 70.00 CALL 100 319
29 Apr 15:53 17 May, 2024 70.00 CALL 76 265
03 May 14:42 17 Jan, 2025 60.00 CALL 12 89
03 May 14:47 16 Jan, 2026 75.00 CALL 12 62
03 May 14:48 16 Jan, 2026 75.00 CALL 13 62
08 May 15:29 21 Jun, 2024 100.00 PUT 15 0
10 May 14:36 21 Jun, 2024 95.00 PUT 15 8
17 May 15:21 17 Jan, 2025 70.00 CALL 100 211
17 May 15:23 17 May, 2024 70.00 CALL 67 300

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the. treatment of smoking cessation. The firm was incorporated in 2012 and is based in New York, New York.

  • Mizuho
    Wed May 8, 07:12
    buy
    confirm
  • Citigroup
    Tue May 7, 13:14
    buy
    confirm
  • Baird
    Tue May 7, 06:45
    buy
    confirm
  • HC Wainwright & Co.
    Tue May 7, 06:30
    buy
    confirm
  • Morgan Stanley
    Mon Apr 29, 05:25
    buy
    upgrade